Impact of thalidomide-based induction regimens on PBSC harvest in multiple myeloma patients

被引：0
|
作者：
Lanska, M. [1 ]
Maisnar, V. [1 ]
Radocha, J. [1 ]
Zak, P. [1 ]
Zavrelova, A. [1 ]
Blaha, M. [1 ]
Horacek, J. [1 ]
Doskocilova, K. [1 ]
Maly, J. [1 ]
机构：
[1] Teaching Hosp, Hradec Kralove, Czech Republic
来源：
BONE MARROW TRANSPLANTATION | 2010年 / 45卷
关键词：
D O I：
暂无
中图分类号：
Q6 [生物物理学];
学科分类号：
071011 ;
摘要：
引用
收藏
页码：S151 / S151
页数：1
相关论文
共 50 条
  • [21] Post-treatment improvement of NK cell numbers predicts better survival in myeloma patients treated with thalidomide-based regimens
    Jorge Vela-Ojeda
    Miriam America García-Ruiz Esparza
    Abraham Majluf-Cruz
    Jaime García-Chavez
    Laura Arcelia Montiel-Cervantes
    Elba Reyes-Maldonado
    Alvaro Hernandez-Caballero
    Maria Guadalupe Rodríguez-González
    International Journal of Hematology, 2019, 110 : 306 - 312
  • [22] A novel panel of protein biomarkers for predicting response to thalidomide-based therapy in newly diagnosed multiple myeloma patients
    Rajpal, Rajesh
    Dowling, Paul
    Meiller, Justine
    Clarke, Colin
    Murphy, William G.
    O'Connor, Robert
    Kell, Malcolm
    Mitsiades, Constantine
    Richardson, Paul
    Anderson, Kenneth C.
    Clynes, Martin
    O'Gorman, Peter
    PROTEOMICS, 2011, 11 (08) : 1391 - 1402
  • [23] The Clinical Impact and Molecular Biology of del(17p) in Multiple Myeloma Treated with Conventional or Thalidomide-Based Therapy
    Boyd, Kevin D.
    Ross, Fiona M.
    Tapper, William J.
    Chiecchio, Laura
    Dagrada, GianPaolo
    Konn, Zoe J.
    Gonzalez, David
    Walker, Brian A.
    Hockley, Sarah L.
    Wardell, Christopher P.
    Gregory, Walter M.
    Child, J. Anthony
    Jackson, Graham H.
    Davies, Faith E.
    Morgan, Gareth J.
    GENES CHROMOSOMES & CANCER, 2011, 50 (10): : 765 - 774
  • [24] Thalidomide overcomes VAD chemoresistance and allows PBSC collection in 3 multiple myeloma patients
    Patriarca, F
    Fill, C
    Sperotto, A
    Damiani, D
    Zaja, F
    Cerno, M
    Fanin, R
    BONE MARROW TRANSPLANTATION, 2002, 29 : S104 - S104
  • [25] Inflammasome and Autophagy Activation In Symptomatic Multiple Myeloma Could Predict Response To Thalidomide-Based Chemotherapy
    Pericole, Fernando V.
    Duarte, Adriana Silva Santos
    Lazarini, Mariana
    Saad, Sara Teresinha Olalla
    BLOOD, 2013, 122 (21)
  • [26] Lenalidomide versus thalidomide based regimens as first-line therapy for patients with multiple myeloma
    Zou, Yandun
    Sheng, Zhixin
    Niu, Shaona
    Wang, Huijuan
    Yu, Jinming
    Xu, Jingbo
    LEUKEMIA & LYMPHOMA, 2013, 54 (10) : 2219 - 2225
  • [27] Impact of thalidomide on survival of patients with multiple myeloma.
    Fawaz, A
    Magro, L
    Leleu, X
    Depil, S
    Guillerm, G
    Corm, S
    Bauters, F
    Facon, T
    Yakoub-Agha, I
    BLOOD, 2002, 100 (11) : 384B - 384B
  • [28] Polymorphisms in the promotor region of the CRBN gene as a predictive factor for peripheral neuropathy in the course of thalidomide-based chemotherapy in multiple myeloma patients
    Mlak, Radoslaw
    Szudy-Szczyrek, Aneta
    Mazurek, Marcin
    Szczyrek, Michel
    Homa-Mlak, Iwona
    Mielnik, Michel
    Chocholska, Sylwia
    Jankowska-Lecka, Olga
    Malecka-Massalska, Teresa
    Hus, Marek
    BRITISH JOURNAL OF HAEMATOLOGY, 2019, 186 (05) : 695 - 705
  • [29] The prognostic impact of 1p21 deletion on newly diagnosed multiple myeloma patients receiving thalidomide-based first-line treatment
    李菲
    ChinaMedicalAbstracts(InternalMedicine), 2013, 30 (04) : 230 - 230
  • [30] Pretransplant Induction Regimens for Multiple Myeloma
    Vesole, David H.
    Siegel, David S.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2015, 21 (02) : 200 - 201
12345